MARKET

MRK

MRK

Merck & Co
NYSE
88.18
+0.63
+0.72%
Opening 14:19 10/04 EDT
OPEN
87.31
PREV CLOSE
87.55
HIGH
88.65
LOW
87.00
VOLUME
3.92M
TURNOVER
162.73M
52 WEEK HIGH
95.72
52 WEEK LOW
69.08
MARKET CAP
223.38B
P/E (TTM)
13.44
1D
5D
1M
3M
1Y
5Y
HHS change to Medicare payments for biosimilars aims to spur uptake
A temporary increase in payments from Medicare for certain biosimilar medications is designed to boost uptake of cheaper versions of high-priced biologic drugs. The increase, which went into effect Monday, is a provision of the Inf...
Seekingalpha · 43m ago
Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype
The U.S. Food and Drug Administration (FDA) <a href="https://seekingalpha.com/pr/18962650-immutep-receives-fda-fast-track-designation-for-lagminus-3-therapeutic-eftilagimod-alpha-for?utm_medium=referral&utm_source=webull.com" target="_blank...
Seekingalpha · 5h ago
The Short List Of Dow Jones Stocks That Are Actually Up This Year: Hint — It's Very Short
The stock market has had a rough going for the first nine months of the year in 2022. All the major indexes are down year-to-date, including the Dow Jones Industrial Average. Here’s a look at the four stocks in the index that have posted positive gains in 2022.
Benzinga · 20h ago
Merck (MRK) Gains But Lags Market: What You Should Know
Merck (MRK) closed at $87.55 in the latest trading session, marking a +1.66% move from the prior day.
Zacks · 21h ago
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.
Benzinga · 2d ago
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still &#34;way too high&#34; on the stock.
Benzinga · 4d ago
10 Analysts Have This to Say About Merck & Co
Merck &amp; Co (NYSE:MRK) has observed the following analyst ratings within the last quarter:
Benzinga · 4d ago
SVB Leerink Maintains Outperform on Merck & Co, Raises Price Target to $110
SVB Leerink analyst Daina Graybosch maintains Merck &amp; Co (NYSE:MRK) with a Outperform and raises the price target from $109 to $110.
Benzinga · 4d ago
More
About MRK
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.

Webull offers kinds of Merck & Co., Inc. stock information, including NYSE:MRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRK stock methods without spending real money on the virtual paper trading platform.